ATAD00086-Lumiliximab ( 鲁昔单抗)

Total Page：16

File Type：pdf, Size：1020Kb

ATAGENIX LABORATORIES Catalog Number:ATAD00086 Lumiliximab ( 鲁昔单抗 ) 产品信息货号（Catalog No.） ATAD00086 通用名INN Lumiliximab 纯度(Purity) >95% 浓度( Concentration) 1mg/ml Formulation PBS buffer PH7.5 Source CHO cells 内毒素(Endotoxin level) Please contact with the lab for this information. 生物活性产品描述(Description) Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug.It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody,for the potential treatment of allergic conditions.Lumiliximab was developed by IDEC Pharmaceuticals,which was acquired by Biogen.Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. Results published from the CLL clinical trial failed to meet primary endpoints.Lumiliximab is a chimeric macaque-human monoclonal antibody to CD23,a protein expressed on virtually all chronic lymphocytic leukemia (CLL) cells.CD23, also known as Fc epsilon RII,or FcεRII,is the "low affinity" receptor for IgE, an antibody isotype involved in allergy and resistance to parasites and is important in regulation of IgE levels. Unlike many of the antibody receptors, CD23 is a C-type lectin. It is found on mature B cells,activated macrophages, eosinophils, follicular dendritic cells and platelets. 别名(Alternative names) IDEC-152,P5E8 靶点;物种(Specificity target name;species) FCER2[Homo sapiens] 种类(Species) Humanized 受体鉴定(Receptor identification) IgG1-kappa 化学信息分子量(MV) 47750.00 Da CAS 357613-86-6 Web:www.atagenix.com E-mail: [email protected] Tel: 027-87433958 ATAGENIX LABORATORIES Catalog Number:ATAD00086 Lumiliximab ( 鲁昔单抗 ) 存储条件(Storage) Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at +4°C short term (1-2 weeks). Store at -20 °C 12 months. Store at -80°C long term. Note For research use only . Web:www.atagenix.com E-mail: [email protected] Tel: 027-87433958.

Copy Link

Recommended publications

Fig. L COMPOSITIONS and METHODS to INHIBIT STEM CELL and PROGENITOR CELL BINDING to LYMPHOID TISSUE and for REGENERATING GERMINAL CENTERS in LYMPHATIC TISSUES
(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date Χ 23 February 2012 (23.02.2012) WO 2U12/U24519ft ft A2 (51) International Patent Classification: AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, A61K 31/00 (2006.01) CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (21) International Application Number: HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, PCT/US201 1/048297 KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, (22) International Filing Date: ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, 18 August 201 1 (18.08.201 1) NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (25) Filing Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (26) Publication Language: English ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/374,943 18 August 2010 (18.08.2010) US kind of regional protection available): ARIPO (BW, GH, 61/441,485 10 February 201 1 (10.02.201 1) US GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, 61/449,372 4 March 201 1 (04.03.201 1) US ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (72) Inventor; and EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, ΓΓ, LT, LU, (71) Applicant : DEISHER, Theresa [US/US]; 1420 Fifth LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, Avenue, Seattle, WA 98101 (US).
[Show full text]
B-Cell Targets to Treat Antibody-Mediated Rejection In
Muro et al. Int J Transplant Res Med 2016, 2:023 Volume 2 | Issue 2 International Journal of Transplantation Research and Medicine Commentary: Open Access B-Cell Targets to Treat Antibody-Mediated Rejection in Transplantation Manuel Muro1*, Santiago Llorente2, Jose A Galian1, Francisco Boix1, Jorge Eguia1, Gema Gonzalez-Martinez1, Maria R Moya-Quiles1 and Alfredo Minguela1 1Immunology Service, University Clinic Hospital Virgen de la Arrixaca, Spain 2Nephrology Service, University Clinic Hospital Virgen de la Arrixaca, Spain *Corresponding author: Manuel Muro, PhD, Immunology Service, University Clinic Hospital “Virgen de la Arrixaca”, Biomedical Research Institute of Murcia (IMIB), Murcia, Spain, Tel: 34-968-369599, E-mail: [email protected] Antibody-mediated rejection (AMR) in allograft transplantation APRIL (a proliferation-inducing ligand). These co-activation signals can be defined with a rapid increase in the levels of specific are required for B-cell differentiation into plasma cell and enhancing serological parameters after organ transplantation, presence of donor their posterior survival and are a key determinant of whether specific antibodies (DSAs) against human leukocyte antigen (HLA) developing B-cells will survive or die during the establishment molecules, blood group (ABO) antigens and/or endothelial cell of immuno-tolerance [5,6]. Important used agents commercially antigens (e.g. MICA, ECA, Vimentin, or ETAR) and also particular available are Tocilizumab (anti-IL6R) and Belimumab (BAFF). histological parameters [1,2]. If the AMR persists or progresses, the The receptors of BAFF and APRIL could also be important as treatment to eliminate the humoral component of acute rejection eventual targets, for example BAFF-R, TACI (transmembrane include three sequential steps: (a) steroid pulses, antibody removal activator and calcium modulator and cyclophyllin ligand interactor) (plasma exchange or immuno-adsorption) and high doses of and BCMA (B-cell maturation antigen).
[Show full text]
Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories
bioRxiv preprint doi: https://doi.org/10.1101/572958; this version posted March 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Title: Looking for Therapeutic Antibodies in Next Generation Sequencing Repositories. Authors: Konrad Krawczyk1*, Matthew Raybould2, Aleksandr Kovaltsuk2, Charlotte M. Deane2 1 NaturalAntibody, Hamburg, Germany 2 Oxford University Department of Statistics, Oxford, UK *Correspondence to [email protected] Abstract: Recently it has become possible to query the great diversity of natural antibody repertoires using Next Generation Sequencing (NGS). These methods are capable of producing millions of sequences in a single experiment. Here we compare Clinical Stage Therapeutic antibodies to the ~1b sequences from 60 independent sequencing studies in the Observed Antibody Space Database. Of the 242 post Phase I antibodies, we find 16 with sequence identity matches of 95% or better for both heavy and light chains. There are also 54 perfect matches to therapeutic CDR-H3 regions in the NGS outputs, suggesting a nontrivial amount of convergence between naturally observed sequences and those developed artificially. This has potential implications for both the discovery of antibody therapeutics and the legal protection of commercial antibodies. Introduction Antibodies are proteins in jawed vertebrates that recognize noxious molecules (antigens) for elimination. An organism expresses millions of diverse antibodies to increase the chances that some of them will be able to bind the foreign antigen, initiating the adaptive immune response.
[Show full text]
Newer Monoclonal Antibodies for Hematological Malignancies
Experimental Hematology 2008;36:755–768 Newer monoclonal antibodies for hematological malignancies Jorge Castillo, Eric Winer, and Peter Quesenberry Division of Hematology and Oncology, Rhode Island Hospital, Brown University Warren Alpert Medical School, Providence, RI, USA (Received 28 March 2008; revised 28 April 2008; accepted 28 April 2008) Since the approval of rituximab in 1997, monoclonal antibodies have come to play an impor- tant role in the therapy of hematological malignancies. Rituximab, gemtuzumab ozogamicin, and alemtuzumab are US Food and Drug Administration–approved for treatment of B-cell lymphomas, acute myeloid leukemia, and chronic lymphocytic leukemia, respectively. Multi- ple monoclonal antibodies directed against new and not-so-new cellular antigens are undergo- ing development and investigation all over the world. Most of these new compounds have undergone primatization or humanization, improving their speciﬁcity and decreasing their antigenicity when compared to earlier murine or chimeric products. This review will focus on three major aspects of monoclonal antibody therapy: 1) new therapeutic approaches with currently approved agents; 2) preclinical and clinical experience accumulated on new agents in the last few years; discussion will include available phase I, II, and III data on ofa- tumumab, epratuzumab, CMC-544, HeFi-1, SGN-30, MDX-060, HuM195 (lintuzumab), galix- imab, lumiliximab, zanolimumab, and apolizumab; and 3) the role of naked and radiolabeled monoclonal antibodies in the hematopoietic stem cell transplantation setting. Ó 2008 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. Since the discovery of hybridoma technology in 1975 [1], or chemotherapy (Table 2). Different strategies of action the production and variety of monoclonal antibodies have have been developed using monoclonal antibodies; these been exponentially increasing.
[Show full text]
I Regulations
23.2.2007 EN Official Journal of the European Union L 56/1 I (Acts adopted under the EC Treaty/Euratom Treaty whose publication is obligatory) REGULATIONS COUNCIL REGULATION (EC) No 129/2007 of 12 February 2007 providing for duty-free treatment for specified pharmaceutical active ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation and specified products used for the manufacture of finished pharmaceuticals and amending Annex I to Regulation (EEC) No 2658/87 THE COUNCIL OF THE EUROPEAN UNION, (4) In the course of three such reviews it was concluded that a certain number of additional INNs and intermediates used for production and manufacture of finished pharmaceu- ticals should be granted duty-free treatment, that certain of Having regard to the Treaty establishing the European Commu- these intermediates should be transferred to the list of INNs, nity, and in particular Article 133 thereof, and that the list of specified prefixes and suffixes for salts, esters or hydrates of INNs should be expanded. Having regard to the proposal from the Commission, (5) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (1) established the Combined Nomenclature Whereas: (CN) and set out the conventional duty rates of the Common Customs Tariff. (1) In the course of the Uruguay Round negotiations, the Community and a number of countries agreed that duty- (6) Regulation (EEC) No 2658/87 should therefore be amended free treatment should be granted to pharmaceutical accordingly, products falling within the Harmonised System (HS) Chapter 30 and HS headings 2936, 2937, 2939 and 2941 as well as to designated pharmaceutical active HAS ADOPTED THIS REGULATION: ingredients bearing an ‘international non-proprietary name’ (INN) from the World Health Organisation, specified salts, esters or hydrates of such INNs, and designated inter- Article 1 mediates used for the production and manufacture of finished products.
[Show full text]
Molecular Targeted Therapies for Indolent Lymphomas: Where Are
Hematology Meeting Reports 2009;3(3):4–9 SESSION I G. Saglio Molecular targeted therapies for indolent G. Parvis M. Bosa lymphomas: where are we? Department of Clinical and Biological Sciences, University of Turin, Regione Gonzole, Orbassano, TO, Italy During the last decade the analysis11 suggested that mainte- development of new drugs for the nance therapy with rituximab, treatment of hematologic malig- either as four weekly infusions nancies has become really prom- every 6 months or as a single infu- ising. This innovative drug devel- sion every 2-3 months, should be opment is based on the translation added to standard therapy for into biochemical pharmacology patients with relapsed or refracto- of specific alterations of biologi- ry follicular lymphoma after suc- cal functions affecting tumour cessful induction therapy, to cells1. One of the most important improve progression-free and examples is imatinib: it showed overall survival. In contrast, pre- that it was possible to nullify the viously untreated patients seem pathognomic genetic lesion of not to acquire the same benefit chronic myelogenous leukemia from the maintenance treatment (CML). Drugs targeting unique (i.e. it prolongs the time to pro- disease-specific pathways have gression but does not prolong sur- also found potential applicability vival).12-13 in treating malignancies such as The data recently showed at CD20-positive non-Hodgkin’s 2008 ASH Meeting, coming from lymphoma (rituximab), follicular the clinical phase III studies lymphoma (Bcl-2-targeted named CLL8 and REACH, defi- agents2-6) and other B-cell neo- nitely support the employment of plasms (splenic tyrosine kinase rituximab in addition to chemo- [Syk] inhibitors;7-9 IkB kinase therapy (the standard regimen inhibitors10).
[Show full text]
Tailored Therapy for Severe Asthma Francesco Menzella1*, Mirco Lusuardi2, Carla Galeone1 and Luigi Zucchi1
Menzella et al. Multidisciplinary Respiratory Medicine 2015, 10:1 http://www.mrmjournal.com/content/10/1/1 REVIEW Open Access Tailored therapy for severe asthma Francesco Menzella1*, Mirco Lusuardi2, Carla Galeone1 and Luigi Zucchi1 Abstract Patients with severe asthma or COPD have often a suboptimal symptom control due to inadequate treatment. A better understanding of pathogenetic mechanisms, phenotypes, endotypes and the new technologies available in the fields of molecular biology and immunogenetics have made it possible to synthesize specific monoclonal antibodies virtually able to interact with any target antigen, or to open a way for new therapeutic target options. At the moment, the only biologic drug available in clinical practice is omalizumab. To overcome the limits of omalizumab, the research has focused on new monoclonal antibodies presenting higher avidity for IgE (e.g. ligelizumab and lumiximab) and ability to interact also with low affinity IgE receptor (FcεRII). At present, many new biological drugs with different mechanisms of action and targets are matter of research. It is very important to identify the asthmatic phenotype in order to select the most appropriate drug for the individual patient. The most promising agents are targeted against cytokines of Th2 pattern and related receptors, such as IL-2 (daclizumab) and IL-13 (lebrikizumab) or IL-5 in patients with hypereosinophilia (mepolizumab, reslizumab and benralizumab). Other interesting drugs have as a target TNF-α or its soluble receptor (infliximab, golimumab and etanercept) or IL-1 (canakinumab), a cytokine with an important systemic proinflammatory action. Finally, the discovery of increased levels of C5a in the airways of asthmatic patients has led to the synthesis of a specific monoclonal antibody (eculizumab).
[Show full text]
New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies
cells Review Checkpoint Inhibitors and Engineered Cells: New Weapons for Natural Killer Cell Arsenal Against Hematological Malignancies Massimo Giuliani 1,* and Alessandro Poggi 2 1 Department of Oncology, Luxembourg Institute of Health, Luxembourg City L-1526, Luxembourg 2 Molecular Oncology and Angiogenesis Unit, IRCCS AOU San Martino IST, 16132 Genoa, Italy; [email protected] * Correspondence: [email protected] Received: 1 June 2020; Accepted: 25 June 2020; Published: 29 June 2020 Abstract: Natural killer (NK) cells represent one of the first lines of defense against malignant cells. NK cell activation and recognition are regulated by a balance between activating and inhibitory receptors, whose specific ligands can be upregulated on tumor cells surface and tumor microenvironment (TME). Hematological malignancies set up an extensive network of suppressive factors with the purpose to induce NK cell dysfunction and impaired immune-surveillance ability. Over the years, several strategies have been developed to enhance NK cells-mediated anti-tumor killing, while other approaches have arisen to restore the NK cell recognition impaired by tumor cells and other cellular components of the TME. In this review, we summarize and discuss the strategies applied in hematological malignancies to block the immune check-points and trigger NK cells anti-tumor effects through engineered chimeric antigen receptors. Keywords: NK cells; hematological malignancies; check-point inhibitors; CAR NK cells; antibodies; immunotherapy 1. Tumor-Mediated NK Cell Exhaustion in Hematological Malignancies NK cells represent one of the first lines of defense against malignant cells. Their immune- surveillance ability is mediated by the expression of activating receptors such as the natural killer group (NKG)2D, DNAX accessory molecule (DNAM)-1, and the natural cytotoxic receptors (NCRs) such as natural killer protein (NKp)30, NKp44, and NKp46 [1–5].
[Show full text]
INN Working Document 05.179 Update 2011
INN Working Document 05.179 Update 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 2011 International Nonproprietary Names (INN) for biological and biotechnological substances (a review) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Essential Medicines and Pharmaceutical Policies (EMP) International Nonproprietary Names (INN) for biological and biotechnological substances (a review) © World Health Organization 2011 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
[Show full text]
Transforming Discovery Into Care 2007 ANNUAL REPORT Highlights
George Harmon TYSABRI Patient Transforming Discovery Into Care 2007 ANNUAL REPORT Highlights MOVING INTO LATE-STAGE TRIALS Biogen Idec moves three programs into late-stage development, initiating Q1 registration trials for lumiliximab in chronic lymphocytic leukemia, galiximab in non-Hodgkin’s lymphoma and BG-12 for multiple sclerosis. INVESTING IN HEMOPHILIA Biogen Idec acquires Syntonix Pharmaceuticals, adding multiple preclinical programs in hemophilia to the pipeline and investing in the $3 billion market for recombinant factor products. DELIVERING SHAREHOLDER VALUE Q2 Biogen Idec returns $3 billion to investors through a share repurchase. POSITIVE RESULTS Biogen Idec and Genentech present detailed positive data from a Phase II clinical study of RITUXAN® (rituximab) in patients with relapsing-remitting multiple sclerosis. Mikael Nilsson Leadership Award Winner MEETING UNMET NEEDS An FDA Advisory Committee recommends approval of TYSABRI® Q3 (natalizumab) for the treatment of moderate-to-severe Crohn’s disease in patients who have failed or cannot tolerate available therapies. GROWING THE PIPELINE Biogen Idec partners with Cardiokine to jointly develop lixivaptan, an oral compound that entered a Phase III clinical trial in February 2008 for the potential treatment of hyponatremia in patients with acute decompensated congestive heart failure. GAINING MOMENTUM Less than 18 months after its reintroduction, TYSABRI exits the year at an Q4 annual run rate of $500 million in worldwide sales. FUELING INNOVATION Biogen Idec announces an alliance with Neurimmune Therapeutics to develop novel, fully human antibodies for the treatment of Alzheimer’s Maureen Shreve disease. It also announced the ﬁrst occupant in the Biogen Idec Innovation Leadership Award Winner Incubator, a corporate initiative designed to contribute to the company’s pipeline by offering entrepreneurial scientists the opportunity to rapidly convert novel biological insights into life-saving and life-changing therapies.
[Show full text]
International Nonproprietary Names for Pharmaceutical Substances (INN)
WHO Drug Information, Vol. 18, No. 3, 2004 Recommended INN: List 52 International Nonproprietary Names for Pharmaceutical Substances (INN) RECOMMENDED International Nonproprietary Names: List 52 Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [Off. Rec. Wld Health Org., 1955, 60, 3 (Resolution EB15.R7); 1969, 173, 10 (Resolution EB43.R9)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy. Lists of Proposed (1–85) and Recommended (1–45) International Nonproprietary Names can be found in Cumulative List No. 10, 2002 (available in CD-ROM only). Dénominations communes internationales des Substances pharmaceutiques (DCI) Dénominations communes internationales RECOMMANDÉES: Liste 52 Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [Actes off. Org. mond. Santé, 1955, 60, 3 (résolution EB15.R7); 1969, 173, 10 (résolution EB43.R9)] les dénominations ci-dessous sont choisies par l’Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L’inclusion d’une dénomination dans les listes de DCI recommandées n’implique aucune recommandation en vue de l’utilisation de la substance correspondante en médecine ou en pharmacie. On trouvera d’autres listes de Dénominations communes internationales proposées (1–85) et recommandées (1–45) dans la Liste récapitulative No. 10, 2002 (disponible sur CD-ROM seulement).
[Show full text]
International Nonproprietary Names (Inn) for Biological and Biotechnological Substances
INN Working Document 05.179 Distr.: GENERAL ENGLISH ONLY 15/06/2006 INTERNATIONAL NONPROPRIETARY NAMES (INN) FOR BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES (A REVIEW) Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines (QSM) Medicines Policy and Standards (PSM) Department CONTENTS 0. INTRODUCTION…………………………………….........................................................................................v 1. PHARMACOLOGICAL CLASSIFICATION OF BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES……………………………………................................1 2. CURRENT STATUS OF EXISTING STEMS OR SYSTEMS FOR BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES…………………….3 2.1 Groups with respective stems ……………………………………………………………………3 2.2 Groups with respective pre-stems………………………………………………………………4 2.3 Groups with INN schemes………………………………………………………………………….4 2.4 Groups without respective stems / pre-stems and without INN schemes…..4 3. GENERAL POLICIES FOR BIOLOGICAL AND BIOTECHNOLOGICAL SUBSTANCES……………………………………………………………………………………………………...5 3.1 General policies for blood products……………………………………………………………5 3.2 General policies for fusion proteins……………………………………………………………5 3.3 General policies for gene therapy products………………………………………………..5 3.4 General policies for glycosylated and non-glycosylated compounds………...6 3.5 General policies for immunoglobulins……………………………………………………….7 3.6 General polices for monoclonal antibodies………………………………………………..7 3.7 General polices for skin substitutes……………………………………………………………9 3.8 General policies for transgenic products……………………………………………………9
[Show full text]